Erratum zu Sollen bei Prodromalstadien der Schizophrenie Antipsychotika zur Psychoseprävention eingesetzt werden? Pro [Nervenarzt, DOI 10.1007/s00115-015-4427-1];Erratum to Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro [Nervenarzt, DOI 10.1007/s00115-015-4427-1];Should antipsychotics be used in prodromal stages of schizophrenia to prevent psychosis? Pro;Sollen bei Prodromalstadien der Schizophrenie Antipsychotika zur Psychoseprävention eingesetzt werden? Pro

Nervenarzt

Volumn 86, Issue 11, 2015, Pages 1420-1423

  Lambert, M ^a   Correll, C ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b ZUCKER HILLSIDE HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT;

ARTICLE; HUMAN; MENTAL PATIENT; PREVENTIVE MEDICINE; PSYCHOPHARMACOTHERAPY; PSYCHOSIS; SCHIZOPHRENIA; COMPLICATION; DOSE RESPONSE; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; PRODROMAL SYMPTOM; PSYCHOLOGY; PSYCHOTIC DISORDERS; TREATMENT OUTCOME;

ANTIPSYCHOTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; PRODROMAL SYMPTOMS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; TREATMENT OUTCOME;

EID: 84946115821     PISSN: 00282804     EISSN: 14330407     Source Type: Journal    
DOI: 10.1007/s00115-015-0055-z     Document Type: Erratum

References (36)

1. Fusar-Poli P, Bonoldi I, Yung AR et al (2012) Predicting psychosis: meta-analysis of transition outcomes in individuals at high clinical risk. Arch Gen Psychiatry 69:220–229
2. Ruhrmann S, Schultze-Lutter F, Salokangas RK et al (2010) Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 67:241–251
3. Cannon TD, Cadenhead K, Cornblatt B et al (2008) Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 65:28–37
4. Marshall M, Rathbone J (2011) Early intervention for psychosis. Cochrane Database Syst Rev 15:CD004718
5. Stafford MR, Jackson H, Mayo-Wilson E et al (2013) Early interventions to prevent psychosis: systematic review and meta-analysis. BMJ 346:185
6. Gaag M van der, Smit F, Bechdolf A et al (2013) Preventing a first episode of psychosis: meta-analysis of randomized controlled prevention trials of 12 month and longer-term follow-ups. Schizophr Res 149:56–62
7. Schmidt SJ, Schultze-Lutter F, Schimmelmann BG et al (2015) EPA guidance on the early intervention in clinical high risk states of psychoses. Eur Psychiatry 30:388–404
8. McGorry PD, Yung AR, Phillips LJ et al (2002) Randomized controlled trial of interventions designed to reduce the risk of progression to first-episode psychosis in a clinical sample with subthreshold symptoms. Arch Gen Psychiatry 59:921–928
9. Phillips LJ, McGorry PD, Yuen HP et al (2007) Medium term follow-up of a randomized controlled trial of interventions for young people at ultra high risk of psychosis. Schizophr Res 96:25–33
10. McGlashan TH, Zipursky RB, Perkins D et al (2006) Randomized, double-blind trial of olanzapine versus placebo in patients prodromally symptomatic for psychosis. Am J Psychiatry 163:790–799
11. Woods SW, Breier A, Zipursky RB et al (2003) Randomized trial of olanzapine versus placebo in the symptomatic acute treatment of the schizophrenic prodrome. Biol Psychiatry 54:453–464
12. McGorry PD, Nelson B, Phillips LJ et al (2013) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: twelve-month outcome. J Clin Psychiatry 74:349–356
13. Yung AR, Phillips LJ, Nelson B et al (2011) Randomized controlled trial of interventions for young people at ultra high risk for psychosis: 6-month analysis. J Clin Psychiatry 72:430–440
14. Phillips LJ, Nelson B, Yuen HP et al (2009) Randomized controlled trial of interventions for young people at ultra-high risk of psychosis: study design and baseline characteristics. Aust N Z J Psychiatry 43:818–829
15. Ruhrmann S, Bechdolf A, Kühn KU (2007) Acute effects of treatment for prodromal symptoms for people putatively in a late initial prodromal state of psychosis. Br J Psychiatry Suppl 51:88–95
16. Woods SW, Tully EM, Walsh BC et al (2007) Aripiprazole in the treatment of the psychosis prodrome: an open-label pilot study. Br J Psychiatry Suppl 51:96–101
17. Kobayashi H, Morita K, Takeshi K et al (2009) Effects of aripiprazole on insight and subjective experience in individuals with an at-risk mental state. J Clin Psychopharmacol 29:421–425
18. Walker EF, Cornblatt BA, Addington J et al (2009) The relation of antipsychotic and antidepressant medication with baseline symptoms and symptom progression: a naturalistic study of the North American Prodrome Longitudinal Sample. Schizophr Res 115:50–57
19. Liu CC, Chien YL, Hsieh MH et al (2013) Aripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label study. J Clin Psychopharmacol 33:18–23
20. Washida K, Takeda T, Habara T et al (2013) Efficacy of second-generation antipsychotics in patients at ultra-high risk and those with first-episode or multi-episode schizophrenia. Neuropsychiatr Dis Treat 9:861–868
21. Tsujino N, Nemoto T, Morita K et al (2013) Long-term efficacy and tolerability of perospirone for young help-seeking people at clinical high risk: a preliminary open trial. Clin Psychopharmacol Neurosci 211:132–136
22. Simon AE, Velthorst E, Nieman DH et al (2011) Ultra high-risk state for psychosis and non-transition: a systematic review. Schizophr Res 132:8–17
23. Howes OD, Kambeitz J, Kim E et al (2012) The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Arch Gen Psychiatry 69:776–786
24. Howes OD, Bose SK, Turkheimer F et al (2011) Dopamine synthesis capacity before onset of psychosis: a prospective [18F]-DOPA PET imaging study. Am J Psychiatry 168:1311–1317
25. Egerton A, Chaddock CA, Winton-Brown TT et al (2013) Presynaptic striatal dopamine dysfunction in people at ultra-high risk for psychosis: findings in a second cohort. Biol Psychiatry 74:106–112
26. Abi-Dargham A, Giessen E van de, Slifstein M et al (2009) Baseline and amphetamine-stimulated dopamine activity are related in drug-naïve schizophrenic subjects. Biol Psychiatry 65:1091–1093
27. Howes O, Bose S, Turkheimer F et al (2011) Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 16:885–886
28. Delespaul PH, de consensusgroep EPA (2013) Consensus regarding the definition of persons with severe mental illness and the number of such persons in the Netherlands. Tijdschr Psychiatr 55:427–438
29. Correll CU (2007) Acute and long-term adverse effects of antipsychotics. CNS Spectr 12(Suppl 21):10–14
30. Aderhold V, Weinmann S, Hägele C et al (2013) Can long-term treatment with antipsychotic drugs lead to structural brain damage? Nervenarzt 84:1117–1119
31. Aderhold V, Weinmann S, Hägele C et al (2015) Frontal brain volume reduction due to antipsychotic drugs? Nervenarzt 86:302–323
32. Fusar-Poli P, Smieskova R, Kempton MJ et al (2013) Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 37:1680–1691
33. Szöke A, Trandafir A, Dupont ME et al (2008) Longitudinal studies of cognition in schizophrenia: meta-analysis. Br J Psychiatry 192:248–257
34. Nielsen RE, Levander S, Kjaersdam Telleus G et al (2015) Second-generation antipsychotic effect on cognition in patients with schizophrenia – a meta-analysis of randomized clinical trials. Acta Psychiatr Scand 131:185–196
35. Lesh TA, Tanase C, Geib BR et al (2015) A multimodal analysis of antipsychotic effects on brain structure and function in first-episode schizophrenia. JAMA Psychiatry 72:226–234
36. Andreasen NC, Liu D, Ziebell S et al (2013) Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. Am J Psychiatry 170:609–615